Fast Discharge After Acute Myocardial Infarction Discharge MI
NCT ID: NCT06744322
Last Updated: 2025-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
2224 participants
INTERVENTIONAL
2024-12-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention
NCT01230606
Effects on Health Status in Patients Early Discharged After Primary Percutaneous Coronary Intervention (PCI)
NCT01244841
Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction
NCT02023983
Intracoronary Administration of Glucocorticoids as a Treatment Method for No-Glucocorticoid Treatment for No-Reflow in STEMI
NCT06552442
Minimal Invasive Procedure for Myocardial Infarction
NCT01360242
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Care
Patients undergo a standard post-infarction care, with discharge at 72 (+/-24 hours) after invasive management of acute myocardial infarction.
No interventions assigned to this group
Fast discharge strategy
Fast discharge at 24 (+/-12) hours after invasive management of acute myocardial infarction.
Fast discharge strategy
Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fast discharge strategy
Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years at time of consent
* Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
* Absence of PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli)
* Ability to understand and willingness to sign and date written informed consent
Exclusion Criteria
* Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI
* Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
* Ongoing respiratory instability defined by Killip class \>I (rales, pulmonary edema)
* Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
* Pregnancy
* Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University Innsbruck
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Reindl, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Medical University Innsbruck
Sebastian J Reinstadler, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Innsbruck
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Wiener Neustadt
Wiener Neustadt, Lower Austria, Austria
Paracelsus Medical University Salzburg
Salzburg, Salzburg, Austria
Cardinal Schwarzenberg Hospital Schwarzach
Schwarzach im Pongau, Schwarzach Im Pongau, Austria
Medical University of Graz
Graz, Styria, Austria
Medical University of Innsbruck
Innsbruck, Tyrol, Austria
University Teaching Hospital Wels-Grieskirchen
Wels, Upper Austria, Austria
Academic Teaching Hospital Feldkirch
Feldkirch, Vorarlberg, Austria
Ludwig Maximilian University Munich
Munich, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20241113-3609
Identifier Type: OTHER
Identifier Source: secondary_id
1284/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.